Sutro Biopharma, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Collaboration and License Agreements and Supply Agreements - Additional Information (Details)

Collaboration and License Agreements and Supply Agreements - Additional Information (Details)			1 Months Ended										3 Months Ended		6 Months Ended		12 Months Ended
	Mar. 31, 2021 USD ($)	May 31, 2019 USD ($)	Jun. 30, 2022 USD ($) Program PerformanceObligation	Apr. 30, 2022 USD ($)	Dec. 31, 2021 USD ($)	Oct. 31, 2021 USD ($)	Aug. 31, 2020 USD ($)	Mar. 31, 2020 USD ($)	Feb. 29, 2020 USD ($)	Sep. 30, 2019 USD ($)	Jul. 31, 2018 USD ($) Program	Aug. 31, 2017 Program	Jun. 30, 2022 USD ($)	Jun. 30, 2021 USD ($)	Jun. 30, 2022 USD ($)	Jun. 30, 2021 USD ($)	Dec. 31, 2021 USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Accounts receivable, reserve for credit losses			$ 0		$ 0								$ 0		$ 0		$ 0
Accounts receivable			97,671,000		12,454,000								97,671,000		97,671,000		12,454,000
BioNova Option Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Deferred revenue			4,000,000.0										4,000,000.0		4,000,000.0
Initial licensing option payment						$ 4,000,000.0
Maximum potential payments related to option exercise, development, regulatory, and commercial milestones						$ 200,000,000
Minimum term of royalties receivable based on annual net sales						10 years
Initial licensing option refundable payment						$ 4,000,000.0
Additional payment required to exercise license option						$ 12,000,000.0
BMS Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Number of programs advancing through preclinical development \| Program												4
Contingent payments		$ 275,000,000.0
Deferred revenue			0		0								0		0		0
2018 BMS Master Services Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Deferred revenue			2,000,000.0		600,000								2,000,000.0		2,000,000.0		600,000
2018 Merck Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Deferred revenue			0		900,000								0		0		900,000
Milestone payment receivable upon initiation of IND enabling toxicology study														$ 15,000,000.0		$ 15,000,000.0
2018 Merck Agreement \| Future Services on Collaboration Joint Steering Committee ("JSC")
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Contingent payment received																	15,000,000.0
Remaining contingent payment received																	300,000
Revenue recognized															300,000
2018 Merck Agreement \| Merck Sharp & Dohme Corp
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Number of target programs \| Program											2
Initial transaction price											$ 60,000,000.0
Upfront payment received															60,000,000.0
Milestone payment received																	2,500,000
Additional milestone payment received																	7,500,000
Revenue recognized															$ 600,000		1,900,000
Revenue recognition aggregate contingent payments eligible to receive																	500,000,000
Milestone method revenue recognition description															If one or more products from the target program is developed for non-oncology or a single indication, the Company will be eligible for reduced aggregate contingent payments. In addition, the Company is eligible to receive tiered royalties ranging from mid-single digit to low teen percentages on the worldwide sales of any commercial products that may result from the collaboration.
First Cytokine-Derivative Program \| Merck Sharp & Dohme Corp
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Upfront payment received								$ 5,000,000.0
Extended research term								1 year
Transaction price	$ 65,000,000.0							$ 65,000,000.0	$ 60,000,000.0					80,000,000.0
Constrained variable consideration									$ 5,000,000.0					15,000,000.0
2020 Merck Master Services Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Deferred revenue			0		0								0		$ 0		0
MDA Agreement \| EMD Serono
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Deferred revenue			0		0								0		0		0
Contingent payment received										$ 1,500,000				2,000,000.0
Milestone payment received							$ 1,000,000.0
Maximum amount eligible to receive for each product developed															52,500,000
2019 EMD Serono Supply Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Deferred revenue			500,000		$ 0								500,000		500,000		0
Supply Agreement \| Vaxcyte, Inc.
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Reimbursements expenses													3,800,000	$ 700,000	6,200,000	$ 1,000,000.0
Tasly License Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Minimum term of royalties receivable based on annual net sales					10 years
Nonrefundable upfront payment receivable					$ 40,000,000.0												40,000,000.0
Maximum potential payments related to development regulatory commercialization contingent payments and milestones				$ 350,000,000.0	345,000,000												$ 345,000,000
Reduction of research and development expenses recognized													0		0
Upfront payment revenue not recognized					$ 40,000,000.0
Initial licensing payment due				25,000,000.0
Initial licensing payment in escrow				$ 15,000,000.0
Upfront payment revenue recognized													25,000,000.0		25,000,000.0
Upfront payment withholding tax amount													2,500,000		2,500,000
Astellas License and Collaboration Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Deferred revenue			$ 90,000,000.0										90,000,000.0		90,000,000.0
Number of target programs \| Program			3
Transaction price			$ 90,000,000.0
Estimated service period			4 years
Revenue recognized													0		0
Upfront payment revenue not recognized			$ 90,000,000.0
Nonrefundable, non-creditable upfront payment receivable			$ 90,000,000.0										90,000,000.0		90,000,000.0
Number of performance obligations \| PerformanceObligation			4
Maximum amount eligible to receive for development, regulatory and commercial milestones for each product candidate			$ 422,500,000										$ 422,500,000		$ 422,500,000
Termination written notice period			30 days